# Tumor Immune Evasion and Pembrolizumab ## How does the PD-1/PD-L1 pathway contribute to tumor immune evasion, and how does pembrolizumab interrupt it? The PD-1/PD-L1 pathway enables tumors to evade immune destruction by suppressing T cell cytolytic activity, inducing T cell exhaustion, and creating adaptive immune resistance through interferon-driven PD-L1 upregulation, while pembrolizumab interrupts this pathway by blocking PD-1/PD-L1 interaction to restore T cell proliferation and effector function, resulting in intratumoral CD8+ T cell expansion and durable tumor regression in 18-76% of patients depending on tumor type and baseline immune infiltration. # Abstract The PD-1/PD-L1 pathway enables tumor immune evasion through multiple mechanisms: direct suppression of T cell function by inhibiting cytokine production and cytolytic activity, induction of T cell exhaustion, and adaptive immune resistance whereby interferon production by tumor-infiltrating CD8+ cells upregulates PD-L1 expression. This interaction dampens T cell proliferation and activation, blocks effector functions, and creates an immunosuppressive tumor microenvironment through upregulation of genes involved in extracellular matrix remodeling and metabolic changes favoring immune evasion. Some CD8+ T cells enter an irreversible dysfunctional state that cannot be rescued by pathway blockade. Pembrolizumab interrupts this pathway by blocking PD-1 interaction with PD-L1 and PD-L2, removing the suppressive effect on T-cell proliferation and immune response. This blockade restores T cell function, leading to increased proliferation of intratumoral CD8+ T cells that directly correlates with tumor size reduction, expansion of memory CD8+ T cells, enhanced effector function marked by granzyme B expression, and development of a more clonal TCR repertoire. Clinical evidence across 10 sources demonstrates objective response rates of 18-76% depending on tumor type and treatment regimen, with responses lasting >1 year in most responders. Pre-existing CD8+ T cells at the invasive tumor margin with close proximity between PD-1 and PD-L1 expressing cells predict response, while higher PD-L1 expression (≥50%) and high tumor mutational burden correlate with improved response rates, though responses occur in PD-L1-negative tumors. # Methods We analyzed 10 sources from an initial pool of 200, using 9 screening criteria. Each paper was reviewed for 9 key aspects that mattered most to the research question. ## Paper search We performed a semantic search across over 138 million academic papers from the Elicit search engine, which includes all of [Semantic Scholar](https://www.semanticscholar.org/) and [OpenAlex](https://openalex.org/). We ran this query: "How does the PD-1/PD-L1 pathway contribute to tumor immune evasion, and how does pembrolizumab interrupt it?" The search returned 200 total results from Elicit. ## Screening We screened in sources based on their abstracts that met certain criteria: - **PD-1/PD-L1 Pathway Focus**: Does the study investigate PD-1/PD-L1 pathway mechanisms in tumor immune evasion OR examine pembrolizumab’s mechanism of action on the PD-1/PD-L1 pathway? - **Clinical Relevance**: Does the study involve human subjects, human tissue samples, or clinically relevant animal models? - **Study Design**: Is the study a randomized controlled trial, observational study, mechanistic study, systematic review, or meta-analysis? - **Relevant Outcomes**: Does the study report on immune response biomarkers, tumor microenvironment changes, or clinical outcomes related to PD-1/PD-L1 modulation? - **Pembrolizumab or PD-1/PD-L1 Inclusion**: If the study focuses on immune checkpoint inhibitors, does it include pembrolizumab or analyze the PD-1/PD-L1 pathway? - **Beyond Pharmacokinetics**: Does the study examine mechanistic or clinical outcomes beyond only pharmacokinetics or drug metabolism? - **Adequate Sample Size**: If the study is a case report or case series, does it include 10 or more patients? - **Human System Validation**: If the study uses in vitro methods with non-human cell lines, does it include validation in human systems? - **Publication Type**: Is the study a full peer-reviewed publication (not a conference abstract, editorial, or opinion piece)? ## Results ### Characteristics of Included Studies The review included 10 sources published between 2012 and 2020, comprising 5 primary clinical studies, 4 review articles, and 1 literature review. | Study | Full text retrieved? | Study Type | Cancer Types | Sample Size | Key Methods | |----------|----------------------|----------------------|---------------------------------------------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------| | A. Ribas et al., 2016 | No | Observational study | Melanoma | 102 tumor biopsies from 53 patients | Multicolor flow cytometry with computational approaches | | J. McDermott & A. Jimeno, 2015 | No | Review | Melanoma, non-small cell lung cancer | N/A | Literature review of preclinical studies and early clinical trials | | K. Mahoney et al., 2015 | Yes | Review of clinical trials| Melanoma | 10-418 patients across multiple trials | Review of clinical trial data and abstracts | | J. Gong et al., 2018 | Yes | Literature review | Melanoma, NSCLC, urothelial carcinoma, HNSCC, classical Hodgkin lymphoma, MSI-H/dMMR solid tumors | N/A | MEDLINE and manual literature search | | P. Tumeh et al., 2014 | Yes | Clinical trial and mechanistic study | Metastatic melanoma | 46 patients with metastatic melanoma; validation cohort of 16 patients | Quantitative immunohistochemistry, multiplex immunofluorescence, next-generation TCR sequencing | | J. Brahmer et al., 2012 | Yes | Phase 1 clinical trial (anti-PD-L1) | Non-small-cell lung cancer, melanoma, colorectal cancer, renal-cell cancer, ovarian cancer, pancreatic cancer, gastric cancer, breast cancer | 207 patients | Intravenous anti-PD-L1 antibody administration, immunohistochemistry, flow cytometry | | S. Topalian et al., 2012 | Yes | Phase 1 clinical trial (anti-PD-1) | Advanced melanoma, non-small-cell lung cancer, castration-resistant prostate cancer, renal-cell cancer, colorectal cancer | 296 patients | Anti-PD-1 antibody administration, immunohistochemistry, flow cytometry | | Z. Xu-Monette et al., 2017 | No | Review | Hodgkin lymphoma, melanoma, advanced cancers | N/A | Review of functional and clinical studies | | J. Miguel et al., 2015 | No | Phase 1 clinical trial | Multiple myeloma (relapsed/refractory) | 34 patients | Modified 3+3 dose-escalation design, pembrolizumab with lenalidomide and dexamethasone | | K. Hudson et al., 2020 | Yes | Review | Melanoma, breast, gastric, ovarian, liver, kidney, pancreatic, bladder, NSCLC, urothelial, Merkel cell carcinomas | N/A | Review of oncology models and clinical data | ### Mechanisms of PD-1/PD-L1 Pathway in Tumor Immune Evasion #### Suppression of T Cell Function The PD-1/PD-L1 pathway serves as a critical immune checkpoint that tumors exploit to evade host immunity. PD-1/PD-L1 interaction suppresses immune responses by reducing T-lymphocyte function and inhibiting cytokine production and cytolytic activity of PD-1-positive, tumor-infiltrating CD4+ and CD8+ T cells. This interaction dampens T cell function and proliferation, blocks effector functions, and reduces T cell killing capacity. #### Adaptive Immune Resistance A key mechanism of immune evasion involves adaptive immune resistance, where PD-L1 expression is upregulated in response to immune attack. Production of interferons by tumor-infiltrating CD8+ cells can induce PD-L1 expression, creating a negative feedback loop. ## Mechanisms by Which Pembrolizumab Interrupts the PD-1/PD-L1 Pathway ### Antibody-Mediated Blockade Pembrolizumab is a highly selective, humanized IgG4 monoclonal antibody designed to block the interaction of PD-1 with its ligands PD-L1 and PD-L2. By preventing PD-1 from binding to PD-L1, pembrolizumab removes the suppressive effect on T-cell proliferation and immune response. ### Restoration of Immune Cell Function Following PD-1 blockade, significant changes occur in immune cell populations and function. CD8+ T cells show increased proliferation within tumors, with responding patients demonstrating increased Ki67 positivity indicating active proliferation and elevated granzyme B expression indicating enhanced effector function. ### Clinical Evidence of Pathway Interruption #### Response Rates Across Cancer Types Clinical trials demonstrated substantial objective response rates across multiple cancer types, providing evidence of successful PD-1/PD-L1 pathway interruption. In melanoma, response rates ranged from 26-45.2%. # Safety Profile ### Immune-Related Adverse Events PD-1/PD-L1 blockade demonstrated a more favorable safety profile compared to previous immunotherapies. Grade 3 or 4 drug-related adverse events occurred in 14% of anti-PD-1-treated patients. ### Management Strategies Management of immune-related toxicities involved glucocorticoids and replacement therapy. # Synthesis The body of evidence demonstrates a coherent mechanistic and clinical narrative for how pembrolizumab interrupts the PD-1/PD-L1 immune evasion pathway. The mechanistic studies provide direct cellular and molecular evidence linking antibody-mediated pathway blockade to restoration of anti-tumor immunity.